Good afternoon and welcome to Revenio, a group earnings call for Q1. My name is Jouni Toijala and I'm the group CEO. And with me here, as normally we have as well our CFO, Robin Pulkkinen. Uh, agenda for today. So I'll start with the highlights for the Q1. Uh, then Robin is going to go through the, uh, financials, shareholder, uh, structure. Uh, plus reiterate, uh, the uh, guidance. Uh, so let's move on to the Q1. So the Q1, uh, started slightly softly, as expected. Uh, however, the cash flow was, uh, strong. So net sales ended up to 23.6 million, reported growth, 1.8%. If we look the currency adjusted number. So that was slightly down, uh, 0.5% EBIT, uh, down from 6.2 to 5.1. Uh, the biggest contributor for that one was the FDA approval related costs. And Robin is going to do a bit more, deeper dive, uh, to the, uh, cost side in his part of the presentation. Cash flow was strong. So, uh, 4.6 million for the Q1. And the big contributor for the good cash flow, uh, was related to the, uh, non-payment, uh, for the long term incentive scheme, plus also really, really minor payments for the short term incentive, uh, schemes. So if going to the business highlights for the for the Q1. So uh, sales in the US and Europe, Middle East and Africa, uh, was strong. Uh, a couple of highlights from the product side, iCare IC200 tonometer. Uh, continued to sell really well like, uh, during the Q4. Uh, also the iCare DRSplus sales was, was really good. Uh, during the Q1 then, as mentioned earlier, uh, so we we we have started to work, uh, with the FDA approval related to the iCare DRSplus. iCare ILLUME screening solution plus the AI, and that cost, uh, occurred, uh, partly during the Q1 this year. So roughly €600,000. Uh, then, uh, if going back to the Q2, Q3, uh, last year. So we had, uh, lots of headwind from the private equity owned optometry sector in the USA. So on the positive note, we saw, uh, some uh, uh, increased activity now during the Q1, uh, from the private equity driven optometry. So that's a clear clearly positive side. Uh, on the product side. iCare's MAIA microperimeter is progressing according to the plan. So based on the current plan, we have the intention to launch the product towards the end of Q4 this year and then, as in all quarters. Lots of activities, of course, related to sustainability themes and especially now during Q1, lots of activities around the double materiality assessment. So that's working according to the plan as well. But over to you, Robin.